The Department of Health and Human Services in November will begin transitioning to commercial distribution an estimated 7.9 million treatment courses of the COVID-19 antiviral pill Paxlovid under an agreement with Pfizer announced. Authorized for emergency use, the supply will remain available for ordering from HHS through Dec. 15, 2023. Beginning in 2024, Pfizer will sell Paxlovid to privately insured patients and operate a federal copay assistance program for these individuals through 2028. Pfizer also will continue to operate a federal assistance program to offer the HHS-procured supply without cost to eligible Medicare, Medicaid and uninsured patients through 2024 and to eligible uninsured and underinsured individuals from 2025 through 2028, updating any expired product. The company also will provide HHS with an additional 1 million treatment courses for the national stockpile. 

Related News Articles

Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…
Headline
The Department of Health and Human Services Oct. 27 urged Merck and Pfizer to work with private insurers to maintain access to their COVID-19 oral antiviral…